Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
29 hedge funds and large institutions have $5.32M invested in Agile Therapeutics in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 15 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
24% less funds holding
Funds holding: 38 → 29 (-9)
40% less capital invested
Capital invested by funds: $8.81M → $5.32M (-$3.49M)
60% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FI
Fosun International
Hong Kong,
China
|
+$171K |
| 2 |
Renaissance Technologies
New York
|
+$158K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$26.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$23.4K |
| 5 |
VF
Virtu Financial
New York
|
+$23.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$1.74M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$302K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$60K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$55K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$25K |
AGRX Hedge Fund Activity: Q3 2018 in Review
29 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q3 2018, worth a combined $5.32M — down 40% from $8.81M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of AGRX and 6 opened new positions — a net loss of 9 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was Fosun International, opening a new position worth an estimated $171K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $1.74M sold.
- 29 institutional investors held Agile Therapeutics (AGRX) as of Q3 2018, down from 38 in Q2 2018.
- Funds reported $5.32M of Agile Therapeutics stock for Q3 2018, down 40% quarter-over-quarter.
- 6 funds opened new Agile Therapeutics positions in Q3 2018 and 15 closed out, a net change of -9 holders.
- The largest Agile Therapeutics buyer in Q3 2018 was Fosun International, an estimated $171K added.
- The largest Agile Therapeutics seller in Q3 2018 was Perceptive Advisors, an estimated $1.74M sold.
Based on aggregated 13F filings for Q3 2018.